Drug intelligence / Profile preview

IVN201

Development stage: Phase 1
Lead developer: ImVisioN
Modality: Vaccines & Immunotherapeutics
Administration: Intralymphatic

Overview

IVN201 is an immunotherapeutic treatment developed for cat dander allergies. It is described as a prophylactic vaccine designed for intralymphatic administration to improve allergen presentation to the immune system. This delivery method aims to achieve faster, more effective desensitization with fewer injections compared to traditional allergy treatments, potentially improving patient compliance.

Other names: TAT-Ii-Fel d 1MAT-Fel d1Modular Allergen Translocation Fel d 1

Beyond the preview

Go deeper on IVN201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVN201.

Explore the full profile